Heather Wakelee, MD

In this final segment, Dr. Sands asks Dr. Cooper to discuss how subcutaneous administration of targeted therapies may influence clinical practice in EGFR-mutated non-small cell lung cancer.

In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that these agents are designed to target the TROP2 antigen on tumor cells and deliver a cytotoxic payload, enabling selective tumor cell killing.

In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.

In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase inhibitor and chemotherapy, now with new brain metastases.

In this segment, Dr. Sands asks Dr. Wakelee how she discusses toxicity profiles and treatment burden with patients when selecting first-line therapy for EGFR-mutated non-small cell lung cancer.

In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases.

In this segment, Dr. Sands asks Dr. Cooper to discuss the role of intracranial efficacy in guiding first-line treatment decisions for EGFR-mutated non-small cell lung cancer.

In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases

Heather Wakelee, MD, and Helena Yu, MD, discuss emerging biomarkers and key evidence gaps in EGFR-mutant NSCLC.

In this segment, Dr. Sands asks Dr. Wakelee to discuss the role of value-based frameworks in evaluating first-line treatment options for EGFR-mutated non-small cell lung cancer.

In this segment, Dr. Sands asks Dr. Cooper to discuss the evolving role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Cooper explains that these agents are designed to deliver cytotoxic payloads directly to tumor cells by targeting TROP2, a surface antigen expressed in many epithelial cancers, thereby enhancing antitumor activity while attempting to limit off-target effects.

Heather Wakelee, MD, and Helena Yu, MD, discuss how to plan long-term treatment sequencing from the time of diagnosis.

In this segment, Dr. Sands asks the panel to reflect on how emerging data presented at recent meetings, including ELCC, are influencing treatment strategies in EGFR-mutated non-small cell lung cancer.

Heather Wakelee, MD, and Helena Yu, MD, discuss how ADCs are being incorporated into sequencing strategies after osimertinib.

Heather Wakelee, MD, and Helena Yu, MD, discuss how TP53 and other co-mutations influence prognosis and sequencing decisions.

In this segment, Dr. Sands invites the panel to discuss how subcutaneous administration may influence treatment experience in EGFR-mutated non-small cell lung cancer, referencing data from the PALOMA-3 trial.

In this segment, Dr. Sands leads a discussion on how clinicians approach risk–benefit assessment in EGFR-mutated non-small cell lung cancer as newer combination strategies become available.

Heather Wakelee, MD, and Helena Yu, MD, discuss when chemotherapy rechallenge may be appropriate in EGFR-mutant NSCLC.

Heather Wakelee, MD, and Helena Yu, MD, examine how FLAURA2 and emerging post-progression data inform sequencing decisions.

Heather Wakelee, MD, and Helena Yu, MD, discuss how they approach patient selection for osimertinib monotherapy vs combination therapy in 2026.

In this segment, Dr. Sands invites Dr. Cooper to explain how she evaluates key efficacy outcomes in selecting first-line therapy for EGFR-mutated non-small cell lung cancer, emphasizing the importance of integrating progression-free survival, overall survival, CNS activity, and patient-specific factors to guide individualized, real-world treatment decisions.

In this opening segment, Dr. Sands invites the panel to outline the current treatment landscape for EGFR-mutated non-small cell lung cancer, with Dr. Wakelee and Dr. Cooper highlighting how recent advances, including data from key phase III trials, are shaping first-line decisions, balancing monotherapy and combination strategies, and integrating efficacy, CNS activity, and tolerability into real-world clinical practice.

The panel discusses treatment considerations for consolidation durvalumab.

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

The panel looks at a second patient case study.

The panel discusses management of resectable early-stage non–small cell lung cancer.

The panel discusses the factors that go into selecting patients for adjuvant therapy.

The panel discusses reassessing for respectability after certain treatments.

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.